Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer

Pediatric Infectious Disease Journal

Volumn 16, Issue 4, 1997, Pages 346-353

  Charnas, Robert ^a   Lüthi, Annette Ridolfi ^b   Ruch, Willy ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

amikacin; ceftazidime; Ceftriaxone; children; fever; neutropenia

Indexed keywords

AMIKACIN; CEFTAZIDIME; CEFTRIAXONE;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LIVER TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TREATMENT OUTCOME;

ADOLESCENT; AMIKACIN; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; FEVER; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INFANT; LEUKEMIA; LYMPHOMA; MALE; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; NEUTROPENIA;

EID: 0343376095     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199704000-00003     Document Type: Article

References (52)

1. Pizzo PA, Rubin M, Freifeld A, Walsh TJ. The child with cancer and infection: I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr 1991;119:679-94.
2. Klastersky J. Therapy for sepsis in neutropenic patients in: Sande MA, Root RK, eds. Treatment of serious infections in the 1990s. Contemporary issues in infectious diseases, vol. 9. Edinburgh: Churchill Livingstone, 1992:47-63.
3. Klastersky J, Zinner SH, Calandra T, et al. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 1988;24(Suppl 1):S35-45.
4. Viscoli C. Aspects of infections in children with cancer. Recent Results Cancer Res 1988;108:71-81.
5. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
6. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-8.
7. The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692-8.
8. Johannson PJH, Stenby E, Ursing B. Septicemia in granulocytic patients: a shift in bacterial etiology. Scand J Infect Dis 1992;24:357-60.
9. Viscoli C, Moroni C, Boni L, et al. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis 1991;13:397-404.
10. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP, Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 1994;120:834-44.
11. Langley J, Gold R. Sepsis in neutropenic children with cancer. Pediatr Infect Dis J 1988;7:34-7.
12. Kapusnik JE, Sande MA. Challenging conventional aminoglycoside dosing regimen. Am J Med 1986;80(Suppl 6B): 179-81.
13. Kovarik JM, Hoepelman IM, Verhoef J. Once daily aminoglycoside administration: new strategies for an old drug. Eur J Clin Microbiol Infect Dis 1989;8:761-9.
14. Powell SH, Thompson WL, Luthe MA, et al. Once-daily vs continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin and tobramycin. J Infect Dis 1983;147:918-32.
15. Ter Braak EW, De Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990;89:58-66.
16. De Vries PJ, Verkooyen RP, Leguit P, Verbrugh HA. Prospective randomized study of once-daily vs. thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990;9:161-8.
17. Hollender LF, Bahnini J, De Manzini N, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother 1989;23:773-83.
18. Sturm A. Netilmicin in the treatment of Gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis 1989;159:931-7.
19. Tulkens P. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother 1991;27(Suppl C):49-61.
20. Nordström L, Ringberg H, Cronberg S, Tjernström O, Walder M. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990;25:159-73.
21. Prins JM, Büller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-9.
22. Mailer R, Ahrne H, Eilard T, Eriksson I, Lausen I, and the Scandinavian Amikacin Once Daily Study Group. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. J Antimicrob Chemother 1991;27(Suppl C):121-8.
23. Meunier F, Van der Auwera P, Aoun M, Ibrahim S, Tulkens PM. Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study. J Antimicrob Chemother 1991;27(Suppl C):129-39.
24. Van der Auwera P, Meunier F, Ibrahim S, Kaufman L, Derde MP, Tulkens PM. Pharmacodynamic parameters of toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother 1991;35:640-7.
25. Roosendaal R, Bakker-Woudenberg IAJM, Van den BergheVan Raffe M, Michel MF. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 1986;30:403-8.
26. Vogelmann B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108:835-40.
27. Craig WA, Vogelmann B. The post antibiotic effect. Ann Intern Med 1987;106:900-2.
28. Frame PT, Phair JP, Watanakunakorn C, Bannister TWP. Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis 1977;135:952-6.
29. Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979;140:576-80.
30. Tran Ba Huy P, Bernard P, Schacht J. Kinetics of gentamicin uptake and release in the rat. J Clin Invest 1986;77:1492-500.
31. Wood CA, Norton DR, Kohi Hepp SJ, et al. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibactericidal efficacy in a rat model of subcutaneous abscess. J Infect Dis 1988;158:13-22.
32. The International Antimicrobial Therapy Cooperative Group of the European Organisation for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-93.
33. Sarubbi FA, Hull JH. Amikacin serum concentrations: prediction of levels and dosage guidelines. Ann Intern Med 1978;89:612-18.
34. Diem K, ed. Geigy scientific tables, vol 2. In: Introduction to statistics, statistical tables, mathematical formulae. 8th ed. Basel: Ciba-Geigy, 1982;89-102, 221-2.
35. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: Wiley 1981:29-30.
36. SAS® Statistics users guide version 6. 4th ed. Cary, NC: SAS Institute, 1991.
37. Red Book. Montvale, NJ: Medical Economics Data, 1993.
38. Kaplan JM, Goretski SA, Keith S, et al. Cost of antibiotic therapy for infants and children. Pediatr Infect Dis J 1990; 9:722-8.
39. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995;29:561-5.
40. Brown AE, Queseda O, Armstrong D. Minimal nephrotoxicity with cephalosporin-aminoglycoside combinations in patients with neoplastic disease. Antimicrob Agents Chemother 1982; 21:592-4.
41. Philips JK, Spearing RL, Crome DJ, Davies JM. Gentamicin volumes of distribution in patients with hematologic disorders. N Engl J Med 1988;319:1290.
42. Zeitany RG, El Saghir NS, Santhosh-Kumar CR, Sigmon MA. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob Agents Chemother 1990;34: 702-8.
43. Hary L, Andrejak M, Bernaert F, Desablens B. Pharmacokinetics of amikacin in neutropenic patients. Curr Ther Res 1989;46:821-7.
44. Higa GM, Murray WE. Alterations in aminoglycoside pharmacokinetics in patients with cancer. Clin Pharm 1987;6: 963-6.
45. Reese RE, Betts RF. Antibiotic use. In: Reese RE, Betts RF, eds. A practical approach to infectious disease. 3rd ed. Boston: Little Brown, 1991:821-1007.
46. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984;149:23-30.
47. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993;71:3640-46.
48. Malik IA, Wajahat AK, Karim M, Aziz Z, Ata Khan M. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98:224-30.
49. Preis S, Juergens H, Friedland C, Oudekotte-David AA, Thomas L, Goebel U. Ceftriaxone alone or in combination with teicoplanin in the management of febrile episodes in neutropenic children and adolescents with cancer on an outpatient base. Klin Pediatr 1993;205:295-9.
50. Kaplinsky C, Drucker M, Goshen J, Tamary H, Cohen IJ, Zaizov R. Ambulatory treatment with ceftriaxone in febrile neutropenic children. Isr J Med Sci 1994;30:649-51.
51. Rapoport BL, Uys A. Open-label comparative study of inpatient versus outpatient treatment in cancer patients with presumed infection with empiric ceftriaxone plus an aminoglycoside and filgrastim [Abstract 19]. Presented at the Second International Symposium on Febrile Neutropenia, Brussels, Belgium, December 14 to 16, 1995.
52. Beveridge RA, Adawadkar S, Miller JA, Kales AN, Binder A, Robert NJ. Outpatient treatment of febrile neutropenia [Abstract 5]. Presented at the Second International Symposium on Febrile Neutropenia, Brussels, Belgium, December 14 to 16, 1995.